- Delivering Pan India
Bleocip® (Bleomycin) 15 unit injection by Cipla. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Bleomycin 15 units (IU) |
|---|---|
| Manufacturer | Cipla |
| Country | India |
| Pack size | 1 vial (15 units/vial) |
| Storage | Store in original pack as per carton instructions |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Bleocip® (Bleomycin) 15 Units Injection — Cytotoxic Glycopeptide Antibiotic: A Sourcing Guide for Hospitals and Oncology Pharmacies
Bleocip® is a brand of bleomycin for injection marketed by Cipla. According to the US prescribing information for bleomycin for injection, bleomycin is considered a palliative treatment and has been shown to be useful in the management of squamous cell carcinoma of the head and neck, penis, cervix and vulva, lymphomas (Hodgkin’s and non-Hodgkin’s), testicular carcinoma, and malignant pleural effusion. Indications for Bleocip in India are defined by its approved pack insert and the Indian regulator. The decision to prescribe bleomycin, including schedule and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Bleocip® (bleomycin) 15 unit vials to hospitals, oncology centres and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the cancer medicines category. Supply is in bulk/wholesale quantities only.
Bleocip contains bleomycin, a mixture of cytotoxic glycopeptide antibiotics, supplied as a sterile powder for injection. The Bleocip carton states it is for intramuscular, intravenous and subcutaneous use.
How it works, according to the label: The US label describes bleomycin as a mixture of cytotoxic glycopeptide antibiotics isolated from a strain of Streptomyces verticillus. Its cytotoxic effect is attributed to causing breaks in the DNA of cancer cells.
The US prescribing information for bleomycin for injection, USP (DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Bleocip pack insert.
Bleomycin is a long-established cytotoxic agent. The reference label states it should be considered a palliative treatment and that the response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Summaries of its evidence base are available from the sources listed at the end of this page, including the National Cancer Institute and the MedlinePlus drug information page. Evidence is cited for information only and is not a recommendation for any patient; the approved prescribing information governs.
| Presentation | Strength | Route (as shown on the carton) |
|---|---|---|
| Sterile powder for injection, single vial in a carton | 15 units (IU) per vial | I.M. / I.V. / Subcutaneous |
Total dose, schedule and administration must be determined by the treating physician and followed as per the approved prescribing information. The label notes that pulmonary toxicity is higher in elderly patients and with higher cumulative doses.
This page is written for hospital pharmacists, oncology department buyers, and pharmacies that source cytotoxic injectables. The US label recommends that bleomycin be administered under the supervision of a qualified physician experienced in cancer chemotherapy.
The US label carries a boxed warning that pulmonary fibrosis is the most severe toxicity associated with bleomycin, most often presenting as pneumonitis, with higher occurrence in elderly patients and those receiving greater than 400 units total dose. It also warns of a severe idiosyncratic reaction (hypotension, mental confusion, fever, chills and wheezing) reported in approximately 1% of lymphoma patients, and of renal or hepatic toxicity. This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Please follow the storage instructions printed on the Bleocip carton and leaflet. For reference, US labels for bleomycin for injection describe the sterile powder as stable under refrigeration at 2°C to 8°C. Hospitals should follow their own cytotoxic-drug handling policies.
Bleocip is marketed by Cipla. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Bleocip through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Bleocip available in India?
A.K. Pharma supplies Bleocip (bleomycin) 15 unit vials to hospitals and pharmacies in India. Contact us for current availability.
What does Bleocip contain?
Bleomycin, a cytotoxic glycopeptide antibiotic, supplied as 15 units per vial for I.M., I.V. or subcutaneous use as per the carton.
Can I order a single vial?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Bleocip be stored?
As printed on the carton and leaflet. Reference US labels describe refrigerated storage at 2°C to 8°C.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
